Retatrutide Phase 3 Results: What 28.3% Weight Loss Means
Retatrutide has officially moved from an exciting Phase 2 story into pivotal Phase 3 territory—and the first obesity results are remarkable.
Lilly has reported results from TRIUMPH-1, a large Phase 3 trial studying the once-weekly triple agonist in adults with obesity or overweight and at least one weight-related condition, without diabetes.
The 28.3% number
At 80 weeks, participants receiving the 12 mg dose lost an average of 70.3 pounds, or 28.3% of their starting body weight. At the 4 mg dose, average loss was 47.2 pounds, or 19.0%.
At 12 mg, 45.3% of participants achieved at least 30% weight loss. In an extension involving participants who started with a BMI of at least 35, average weight reduction reached 30.3% at 104 weeks.
Those numbers deserve attention, but the mechanism is just as interesting to me.
Why retatrutide is different
Retatrutide activates three receptors: GIP, GLP-1, and glucagon. Semaglutide targets one major incretin pathway. Tirzepatide targets two. Retatrutide is testing whether intentionally adding glucagon-receptor activity can push metabolic treatment into another range.
The study does not prove that more receptors automatically means a better medication for every patient. It does show that triple-agonist pharmacology is now producing pivotal-trial results that are difficult to ignore.
What about tolerability?
As in earlier studies, gastrointestinal effects were among the most common adverse events. Dose escalation remains an important part of how these medications are studied because tolerability can influence how much medication a person can actually stay on.
Where is retatrutide in the FDA journey?
TRIUMPH-1 is a pivotal Phase 3 trial—the type of study that can become part of a future FDA application. But a drug-development program usually includes multiple Phase 3 studies across different populations and outcomes, plus the manufacturing and quality information needed for a regulatory submission.
So this is not the FDA decision point yet. It is, however, exactly the kind of milestone that brings that future step much closer.
What I am watching next
I want to see the rest of the Phase 3 program, including data in people with type 2 diabetes and obesity-related complications. Retatrutide is no longer only a 'drug to watch someday.' The late-stage evidence is arriving now.
Comments